Skip to main content
. Author manuscript; available in PMC: 2023 May 24.
Published in final edited form as: J Neuroimmune Pharmacol. 2021 Nov 10;17(1-2):15–32. doi: 10.1007/s11481-021-10023-6

Fig. 1.

Fig. 1

CBD ameliorates EAE symptomology. (A) Clinical scores, outlined in the Materials and Methods section, over time of EAE mice receiving either vehicle (n=15) or CBD treatment (n=15) by oral gavage at a dose of 20 mg/kg body weight. (B) Composite score of paralysis symptoms per mouse. (C) Change in body weight represented as a percentage of starting body weight. (D) Body weight over time